By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 

1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.


Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 



Industry
Pharmaceutical






Company News
Bristol-Myers Squibb (BMY) And AbbVie (ABBV) Receive Positive CHMP Opinion Forinvestigational Antibody, Empliciti (Elotuzumab), For The Treatment Of Multiple Myeloma In Patients Who Have Received At Least One Prior Therapy 1/29/2016 9:17:12 AM
AbbVie (ABBV) Reports Full-Year 2015 and Fourth-Quarter Financial Results 1/29/2016 7:05:03 AM
AbbVie (ABBV)'s Venetoclax Wins 3rd Breakthrough Tag from the FDA 1/28/2016 5:58:34 AM
AbbVie (ABBV) Initiates Enrollment In Phase 3 Clinical Program For Elagolix In Patients With Uterine Fibroids 1/28/2016 5:58:12 AM
MD Anderson Cancer Center, AbbVie (ABBV) Connect To Advance Cancer Immunotherapy 1/21/2016 6:59:43 AM
AbbVie (ABBV) and Roche (RHHBY)'s Venetoclax Snags Breakthrough Tag from the FDA for Blood Cancer 1/20/2016 7:39:17 AM
AbbVie (ABBV) CEO Argues Value of Company‚Äôs Pipeline, Piques Analysts Interest 1/20/2016 6:44:02 AM
Amgen (AMGN) Cringes as Officials Reject Petition Against AbbVie (ABBV) Patents 1/15/2016 6:21:25 AM
U.S. and European Regulators Accept Applications For AbbVie (ABBV)'s Venetoclax, The First Potential BCL-2 Inhibitor For Chronic Lymphocytic Leukemia 1/12/2016 9:18:37 AM
Enanta Pharmaceuticals, Inc. Announces That AbbVie (ABBV) Has Initiated Enrollment Of Six Global Phase 3 Clinical Studies Of Its Once-Daily, Pan-Genotypic Hepatitis C Treatment 1/11/2016 12:57:12 PM
12345678910...
//-->